Substituted Beta-Lactams for Glaucoma via EP2 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly ocular hypertension, often rely on topical β-adrenoreceptor antagonists, which may not adequately address the underlying intraocular pressure issues, and existing prostaglandin EP2 agonists have broad medical uses but specific compounds for glaucoma management are limited.
Innovation Solution
Development of a compound comprising a specific structural formula with an organic acid functional group, amide, ester, hydroxymethyl, or tetrazolyl functional group, designed to be active at the prostaglandin EP2 receptor for the treatment of glaucoma or ocular hypertension, including various pharmaceutical forms like salts, prodrugs, and metabolites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical β-adrenoreceptor antagonists are used for treating glaucoma, then intraocular pressure can be reduced, but the treatment may not adequately address the underlying pathophysiology and has limited efficacy
Solution Approach 1:
The patent changes the pharmacological parameter from β-adrenoreceptor antagonism to prostaglandin EP2 receptor agonism, representing a fundamental shift in the mechanism of action. This parameter change enables the drug to address the underlying pathophysiology of aqueous humor outflow obstruction by directly stimulating uveoscleral outflow pathways, thereby improving both reliability and adaptability of the treatment
Solution Approach 2:
The prostaglandin EP2 agonist compound serves multiple functions: it reduces intraocular pressure through uveoscleral outflow enhancement, addresses the underlying pathophysiology of aqueous humor drainage obstruction, and provides a novel mechanism of action that complements or alternatives to traditional β-blockers, thereby achieving versatile treatment coverage
2Adaptability or versatility
If existing prostaglandin EP2 agonists with broad medical uses are employed, then various conditions can be treated, but specific compounds optimized for glaucoma management are limited
Solution Approach 1:
The patent applies local quality by designing the prostaglandin EP2 agonist with specific structural modifications (substituted phenylpiperazine moiety at position 2 of the prostanoic acid skeleton) that optimize its affinity and selectivity for the EP2 receptor in ocular tissues. This localized structural optimization enhances the compound's effectiveness specifically for glaucoma treatment while maintaining its prostaglandin EP2 agonist activity
Solution Approach 2:
The molecular structure is segmented into distinct functional domains: the prostanoic acid core provides the prostaglandin scaffold, the substituted phenylpiperazine group at position 2 confers EP2 receptor selectivity, and additional substituents fine-tune pharmacokinetic properties. This segmentation allows independent optimization of receptor binding and tissue distribution for glaucoma-specific efficacy
Data Source
AI summary
Disclosed herein is a compound comprisingor a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;wherein Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;A is —(CH2)6—, cis —CH2CH═CH—(CH2)3—, or —CH2C≡C—(CH2)3—, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH2 may be substituted with S or O; andD is aryl or heteroaryl.